AI-Designed Binding Proteins are Transforming Biologics Workflows

The biologics landscape is evolving rapidly. From monoclonal antibodies to antibody-drug conjugates (ADCs), bispecifics, and nanobodies, today’s therapeutic pipelines demand higher throughput, better data quality, and faster iteration cycles.

At the center of this shift is a convergence of AI-driven protein design and label-free analytical technologies, enabling researchers to overcome longstanding bottlenecks in binding analysis, assay development, and early-stage screening.

A new generation of computationally engineered binding proteins is redefining how laboratories approach biolayer interferometry (BLI) and antibody characterization.

 

How traditional binding assays are reaching their limits

Biolayer interferometry (BLI) has long been a workhorse for real-time, label-free kinetic analysis. Its advantages are well established:

  • Real-time monitoring of association/dissociation kinetics
  • Minimal sample preparation
  • Compatibility with crude or partially purified samples
  • High-throughput formats (96- and 384-well)

However, conventional antibody-based BLI capture probes introduce several persistent challenges, including:

  • Baseline drift, reducing data reliability
  • Low signal resolution, particularly for weak or ultra-tight binders
  • Fc-mediated non-specific interactions, leading to false positives
  • Limited regeneration capacity, increasing consumable costs

These limitations become especially problematic when working with picomolar affinity interactions or complex biological matrices.

 

Recent advances in computational protein design

AI-based modeling approaches have now enabled the creation of engineered binding scaffolds optimized for stability, specificity, and optical performance.

Expanded BLI Applications using computationally designed probes include:

  1. High-fidelity kinetic analysis
  2. Quantitation and titer analysis
  3. High-throughput epitope binning
  4. Fc receptor and interaction studies
  5. Cell-free screening workflows
  6. Accelerated antibody discovery pipelines

 

The bigger picture: AI-driven protein engineering

The emergence of AI-designed binding proteins signals a broader shift in life sciences:

  • Custom-designed scaffolds tailored to specific assay needs
  • Improved reagent reproducibility and performance
  • Faster translation from discovery to therapeutic development

 

Download the Full Whitepaper and uncover detailed performance data, workflow diagrams, and application case studies demonstrating how AI-designed probes are transforming BLI assays, antibody discovery, and the biologics development pipeline.